Study of Apatinib and MASCT in Patients With Advanced Solid Tumors

Sponsor
The First People's Hospital of Lianyungang
Study ID
NCT02844881
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

  • Advanced Solid Tumors
  • Excluding T Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib 850 mg p.o. qd every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
  • MASCT — BIOLOGICAL
    Dendritic cells(DC) loaded with 17 antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

Study Details

The study is aimed to evaluate the efficacy and safety of Apatinib and MASCT in patients with advanced solid tumors.

Key Dates

First listed
Jul 26, 2016
Start date
Jul 31, 2016
Status verified
Jul 2016
Primary completion
Jul 31, 2018
Completion
Jul 31, 2018

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib+MASCT
    Apatinib+Multiple Antigens Specific Cellular Therapy(MASCT) in patients with advanced solid tumors,excluding T cell lymphoma

Primary Outcome Measure

Incidence of treatment-related adverse events [ Time Frame: up to 2 years ]

Central Contacts

Related Studies